Study presented by Dr. Michaela Koehm evaluated benefit of MTX in combination with ustekinmuab in PsA w/1° outcome of non-inferiority to placebo @ DAS28 @ wk 24.
🔹Randomized 173 pts
🔹52 weeks
🔹1° met
(continued below)
https://t.co/65ZXDjG9ur
#ACR21 Abst#L12 @RheumNow https://t.co/KsBbwJuLe8
Links:
Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23 Inhib…
https://bit.ly/3wAJcV9
10-11-2021